Ultima Genomics reported it doubled its installed base in 2025, expanded partnerships with vendors like 10x Genomics and Twist Biosciences, and entered 2026 with a contracted revenue backlog more than double 2025 revenue. The company said Q4 consumables revenue grew sharply and half of its installs are for clinical use. Element Biosciences disclosed plans to launch two new sequencing systems in 2026, including an IVDR‑qualified Aviti variant and a benchtop platform targeting a $100 genome and upgradeable multiomic capabilities. Collectively, these updates signal continued competition and product expansion in high‑throughput and low‑cost sequencing hardware — a dynamic that will influence genomic assay economics and clinical adoption.